US75382E1091 - Common Stock
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics...
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Monday's session: top gainers and losers
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
What's going on in Monday's pre-market session
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RAPT Therapeutics (NASDAQ:RAPT) just reported results for the second quarter of...
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics...
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Company maintains solid cash position of $141.6 million
Company maintains solid cash position of $141.6 million...
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with...
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RAPT Therapeutics (NASDAQ:RAPT) just reported results for the fourth quarter of...
Company maintains solid cash position of $158.9 million
Company maintains solid cash position of $158.9 million...
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer...